A phase i dose escalation and pharmacodynamic study of SU5416 (Semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors

Ludmila K. Martin, Tanios Bekaii-Saab, Derek Serna, Paul Monk, Steven K. Clinton, Michael R. Grever, Eric H. Kraut

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'A phase i dose escalation and pharmacodynamic study of SU5416 (Semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences